U.S., July 10 -- ClinicalTrials.gov registry received information related to the study (NCT07055451) titled 'Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Newborns Exposed to HIV' on June 27.
Brief Summary: The goal of this clinical study is to learn more about the study drug, Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), safety, tolerability, and pharmacokinetics (how B/F/TAF is absorbed, modified, distributed, and removed from the body of the participants) in neonates exposed to human immunodeficiency virus type 1 (HIV-1).
The primary objective of this study is to evaluate the safety and plasma pharmacokinetics (PK) (how B/F/TAF is absorbed, modified, distributed, and removed from the body of the participants)...